CTNI-08. A PHASE 1–2 CLINICAL TRIAL OF EO1001, A NOVEL IRREVERSIBLE PAN-ErbB INHIBITOR WITH PROMISING BRAIN PENETRATION

Mutations causing errant ErbB activation are implicated in many cancers, including tumors correlated with high incidence of CNS metastasis. ErbB family member “crosstalk” is associated with rapid development acquired resistance to ErbB TKIs, particularly in advanced disease. The development of agent...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Wheeler, Helen, Bacha, Jeffrey, Brown, Dennis, Kanekal, Sarath, Sankar, Neil, Nisbet, Ian, Skoff, Kathy, Shen, Wang, ZhenZhong, Wang, Pedersen, Harry
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650483/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.175
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados